| The Impact of First-Line Treatment on Subsequent Treatment Options for Metastatic ESCC | 04/17/2025 | |
| Tailoring First-Line Regimens: Patient-Centric Selection in Metastatic ESCC | 04/17/2025 | |
| Strategies for Navigating First-Line Treatment Selection in Metastatic ESCC | | |
| ICI Combination Regimens for First-Line Treatment of Metastatic ESCC | 04/16/2025 | |
| Effective Monitoring and Management of Adverse Effects in Metastatic ESCC | 04/15/2025 | |
| Distinguishing Between Anti-PD-1 Agents in ESCC Combination Therapies | 04/16/2025 | |
| Differentiating First-Line Treatment Selection: Combination Immunotherapy and Chemotherapy Regimens… | | |
| HER2-Directed ADCs in Gastric Cancer | 05/31/2023 | |
| A Deep Dive into the Management of AEs Associated with ADCs | | |
